{'fraction_non_alphanumeric': 0.013333333333333334, 'fraction_numerical': 0.0, 'mean_word_length': 6.805194805194805, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Does protein aggregation drive postmitotic tissue degeneration?

Pharmacological evidence from clinical trials demonstrates that protein aggregation drives tissue degeneration in systemic amyloid diseases. Pharmacological evidence, from clinical trials where patients with systemic amyloid diseases are treated with disease-modifying therapies, supports the notion that protein aggregation drives tissue degeneration in these disorders. The protein aggregate structures driving tissue pathology and the commonalities in etiology between these diseases and Alzheimer’s disease are under investigation.